Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11615257 | 0.96 | LMNA (0.66) | LMNASMN1; SMN2GAAALDH1A1HTT | |
| SCHEMBL1443608 | 0.88 | ALDH1A1 (0.55) | LMNASMN1; SMN2GAAALDH1A1HTT | |
| SCHEMBL3327607 | 0.88 | LMNA (0.55) | LMNASMN1; SMN2GAAALDH1A1HTT | |
| SCHEMBL8973821 | 0.82 | HTT (0.63) | LMNASMN1; SMN2GAAALDH1A1HTT | |
| SCHEMBL14735692 | 0.81 | GBA1 (0.69) | LMNASMN1; SMN2GAAALDH1A1HTT | |
| SCHEMBL6715927 | 0.81 | KMT2A (0.60) | LMNASMN1; SMN2GAAALDH1A1HTT | |
| SCHEMBL9418611 | 0.80 | HTT (0.61) | LMNASMN1; SMN2GAAALDH1A1HTT | |
| SCHEMBL14735802 | 0.80 | LMNA (0.81) | LMNASMN1; SMN2GAAALDH1A1HTT | |
| SCHEMBL28677082 | 0.80 | LMNA (0.47) | LMNASMN1; SMN2GAAALDH1A1HTT | |
| SCHEMBL11766675 | 0.79 | KMT2A (0.63) | LMNASMN1; SMN2GAAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214982-A1 | COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-07-03 | — | — | US | disclosed |
| EP-4499615-A1 | COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY | Ramot at Tel-Aviv University Ltd. (IL) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023187783-A1 | COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-10-05 | — | — | WO | disclosed |
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-2473486-B1 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| EP-2473486-B1 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| EP-1877388-A2 | HYDRAZINOMETHYL, HYDRAZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | Kudos Pharmaceuticals Ltd (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20060199804-A1 | Compounds | KUDOS PHARMACEUTICALS LTD (GB) | 2006-09-07 | — | — | US | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| US-4033957-A | Triazine derivatives as stabilizers for organic materials | SANDOZ LTD. (CH) | 1977-07-05 | — | — | US | disclosed |
| US-3957765-A | ANTIOXIDANTS, PLASTICS | SANDOZ LTD. (CH) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | HAMP, DHPS, SLC40A1 | LMNA 4333/4885SMN1; SMN2 4562/4885GAA 1717/4885 |
| US-20060199804-A1 | Compounds | CA4, CA6, CYP2B6 | LMNA 2032/4885SMN1; SMN2 3727/4885GAA 3914/4885 |
| US-20250214982-A1 | COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY | ATF4, ERN1, ERN2 | LMNA 2801/4885SMN1; SMN2 693/4885GAA 494/4885 |
| US-20100130473-A1 | COMPOUNDS | CA6, CYP2B6, CA4 | LMNA 2245/4885SMN1; SMN2 3985/4885GAA 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.